Last reviewed · How we verify
Adjuvanted QIV (aQIV)
Adjuvanted QIV (aQIV) is a quadrivalent influenza vaccine enhanced with an adjuvant to boost immune response against four influenza virus strains.
Adjuvanted QIV (aQIV) is a quadrivalent influenza vaccine enhanced with an adjuvant to boost immune response against four influenza virus strains. Used for Seasonal influenza prevention in adults.
At a glance
| Generic name | Adjuvanted QIV (aQIV) |
|---|---|
| Sponsor | Seqirus |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
aQIV combines a standard inactivated quadrivalent influenza vaccine (QIV) with an adjuvant system designed to enhance and broaden the immune response. The adjuvant amplifies both antibody production and cellular immunity against the vaccine antigens, potentially providing improved protection compared to non-adjuvanted formulations, particularly in older adults or immunocompromised populations.
Approved indications
- Seasonal influenza prevention in adults
Common side effects
- Injection site pain/erythema
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older (PHASE3)
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above (PHASE3)
- A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age (PHASE3)
- Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (PHASE3)
- Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 (PHASE3)
- Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age (PHASE3)
- Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvanted QIV (aQIV) CI brief — competitive landscape report
- Adjuvanted QIV (aQIV) updates RSS · CI watch RSS
- Seqirus portfolio CI